Literature DB >> 32943282

Cardiac involvement in adult-onset Still's disease: Manifestations, treatments and outcomes in a retrospective study of 28 patients.

Quentin Bodard1, Vincent Langlois2, Philippe Guilpain3, Alain Le Quellec3, Olivier Vittecoq4, David Noel5, Vincent Eble6, Séverine Josse7, Jean Schmidt8, Achille Aouba9, Hervé Levesque10, Maelle Le Besnerais10, Ygal Benhamou10.   

Abstract

OBJECTIVE: Adult-onset Still's disease (AOSD) is a rare inflammatory disease that may be life-threatening if complicated by cardiac problems. We performed a retrospective multicenter study to describe the manifestations, treatments and outcomes of cardiac involvement in AOSD.
METHODS: We reviewed the medical databases of eight centers. All AOSD patients identified as fulfilling Yamagushi's or Fautrel's criteria were included in the study. Cardiac involvement, clinical manifestations, laboratory features, the course of the disease and treatments were evaluated.
RESULTS: We included 96 AOSD patients in this study: 28 (29%) had documented cardiac involvement (AOSD + C group) and 68 (71%) had no cardiac involvement (control group). Cardiac complications were observed at diagnosis in 89% of cases. It were pericarditis (n = 17), tamponade (n = 5), myocarditis (n = 5) and non-infectious endocarditis (n = 1). Levels of leukocytes, neutrophils and C-reactive protein were significantly higher (p = 0.02, p = 0.02 and p = 0.002, respectively in the AOSD + C group than in the control group. Admission to intensive care, and the use of biotherapy were more frequent during follow-up in the AOSD + C group than the control group (p = 0.0001 and p = 0.03 respectively). Cardiac involvement was associated with refractory form in multivariate analyzed (p = 0.01). Corticosteroids were effective with or without methotrexate in 71% of patients but not in severe involvement as myocarditis or tamponade.
CONCLUSION: Cardiac complications are frequent, inaugural, can be life-threatening and predictive of a refractory course in patients with AOSD. Systematic cardiac screening should be proposed at diagnosis and biotherapy early use should be considered especially in myocarditis.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adult-onset Still's disease; Biotherapy; Cardiac involvement; Myocarditis; Pericarditis; Tamponade

Year:  2020        PMID: 32943282     DOI: 10.1016/j.jaut.2020.102541

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  5 in total

1.  Cardiac Tamponade as a Rare Presentation of Adult-Onset Still's Disease.

Authors:  Shadi Daoud; Lean Alkhatib; Aseel Nimri; Ahmad S Matarneh
Journal:  Cureus       Date:  2021-12-03

2.  Autoinflammation leading to autoimmunity in adult-onset Still's disease: more than simple coincidence?

Authors:  Larissa Valor-Méndez; Bernhard Manger; Alexander Cavallaro; Stephan Achenbach; Georg Schett; Jürgen Rech
Journal:  Eur J Med Res       Date:  2021-09-20       Impact factor: 2.175

Review 3.  Update on the therapy of adult-onset Still's disease with a focus on IL-1-inhibition: a systematic review.

Authors:  Claudia Kedor; Stylianos Tomaras; Daniel Baeumer; Eugen Feist
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-11-24       Impact factor: 5.346

Review 4.  Cardiac Magnetic Resonance in Rheumatology to Detect Cardiac Involvement Since Early and Pre-clinical Stages of the Autoimmune Diseases: A Narrative Review.

Authors:  Lilia M Sierra-Galan; Mona Bhatia; Angel Leovigildo Alberto-Delgado; Javier Madrazo-Shiordia; Carlos Salcido; Bernardo Santoyo; Eduardo Martinez; Maria Elena Soto
Journal:  Front Cardiovasc Med       Date:  2022-07-13

5.  Circulating Neutrophil Extracellular Traps Signature for Identifying Organ Involvement and Response to Glucocorticoid in Adult-Onset Still's Disease: A Machine Learning Study.

Authors:  Jinchao Jia; Mengyan Wang; Yuning Ma; Jialin Teng; Hui Shi; Honglei Liu; Yue Sun; Yutong Su; Jianfen Meng; Huihui Chi; Xia Chen; Xiaobing Cheng; Junna Ye; Tingting Liu; Zhihong Wang; Liyan Wan; Zhuochao Zhou; Fan Wang; Chengde Yang; Qiongyi Hu
Journal:  Front Immunol       Date:  2020-11-09       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.